{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:28:45Z","timestamp":1790252925113,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HIV\/HCV infection is supposed to substantially reduce survival as compared to HIV mono-infection. Here, we compared longtime-survival and causes of death in a cohort of HIV- and HIV\/HCV-co-infected patients on combined antiretroviral therapy (cART), before introduction of HCV direct acting antivirals (DAA). 322 Caucasian patients with HIV (n\u2009=\u2009176) and HIV\/HCV-infection (n\u2009=\u2009146) were enrolled into this study. All patients were recruited between 2003 and 2004 and followed until 01.01.2014. We compared overall survival between the two groups by the Kaplan-Meyer method and identified independent factors associated with long-time survival by conditional Cox regression analysis. In total 46 (14.3%) patients died during the observation period (HIV infection: n\u2009=\u200923 (13.1%), HIV\/HCV infection: n\u2009=\u200923 (15.8%) but overall-survival did not differ significantly between HIV\/HCV-infected and HIV mono-infected patients (p\u2009=\u20090.619). Survival was substantially better in patients with complete suppression of HIV replication below the level of detection than in those with residual viremia (p\u2009=\u20090.001). Age (p\u2009=\u20090.008), \u03b3-glutamyltranspeptidase (p\u2009&lt;\u20090.0001) and bilirubin (p\u2009=\u20090.008) were significant predictors of survival irrespective from HCV co-infection. Complete repression of HIV replication on cART is the key factor determining survival both in HIV- and HIV\/HCV-co-infected patients, while HCV co-infection and therapy without DAAs seem to affect survival to a lesser extent. Thus, patients with HIV\/HCV co-infection require particularly intensive cART.<\/jats:p>","DOI":"10.1038\/s41598-019-48756-3","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T10:03:26Z","timestamp":1567073006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Survival of HIV\/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)"],"prefix":"10.1038","volume":"9","author":[{"given":"L.","family":"Dold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schwarze-Zander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Boesecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Langhans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-C.","family":"Wasmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. P.","family":"Strassburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. K.","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Spengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"issue":"2","key":"48756_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1055\/s-0032-1316468","volume":"32","author":"C Boesecke","year":"2012","unstructured":"Boesecke, C. & Rockstroh, J. K. Acute hepatitis C in patients with HIV. Seminars in liver disease 32(2), 130\u20137 (2012).","journal-title":"Seminars in liver disease"},{"issue":"2","key":"48756_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/0956462416630910","volume":"28","author":"AE Jordan","year":"2017","unstructured":"Jordan, A. E. et al. Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis. International journal of STD & AIDS 28(2), 145\u201359 (2017).","journal-title":"International journal of STD & AIDS"},{"issue":"7","key":"48756_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","volume":"16","author":"L Platt","year":"2016","unstructured":"Platt, L. et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. The Lancet Infectious diseases 16(7), 797\u2013808 (2016).","journal-title":"The Lancet Infectious diseases"},{"issue":"12","key":"48756_CR4","first-page":"2563","volume":"91","author":"JK Rockstroh","year":"1996","unstructured":"Rockstroh, J. K. et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. The American journal of gastroenterology 91(12), 2563\u20138 (1996).","journal-title":"The American journal of gastroenterology"},{"issue":"1","key":"48756_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/jvh.12447","volume":"23","author":"JV Fernandez-Montero","year":"2016","unstructured":"Fernandez-Montero, J. V., Barreiro, P., de Mendoza, C., Labarga, P. & Soriano, V. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. Journal of viral hepatitis 23(1), 47\u201352 (2016).","journal-title":"Journal of viral hepatitis"},{"issue":"11","key":"48756_CR6","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1158\/1055-9965.EPI-06-0308","volume":"15","author":"L Dal Maso","year":"2006","unstructured":"Dal Maso, L. & Franceschi, S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 15(11), 2078\u201385 (2006).","journal-title":"Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"issue":"9939","key":"48756_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","volume":"384","author":"CJ Smith","year":"2014","unstructured":"Smith, C. J. et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 384(9939), 241\u20138 (2014).","journal-title":"Lancet"},{"issue":"Suppl 2","key":"48756_CR8","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1086\/381453","volume":"38","author":"M Bonacini","year":"2004","unstructured":"Bonacini, M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 38(Suppl 2), S104\u20138 (2004).","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"10","key":"48756_CR9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/QAD.0000000000000674","volume":"29","author":"D Grint","year":"2015","unstructured":"Grint, D. et al. Liver-related death among HIV\/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. Aids 29(10), 1205\u201315 (2015).","journal-title":"Aids"},{"issue":"10","key":"48756_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/j.1365-2893.2012.01596.x","volume":"19","author":"T Suarez-Zarracina","year":"2012","unstructured":"Suarez-Zarracina, T. et al. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients. Journal of viral hepatitis 19(10), 685\u201393 (2012).","journal-title":"Journal of viral hepatitis"},{"issue":"4","key":"48756_CR11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/COH.0b013e3283473405","volume":"6","author":"H Kovari","year":"2011","unstructured":"Kovari, H. & Weber, R. Influence of antiretroviral therapy on liver disease. Current opinion in HIV and AIDS 6(4), 272\u20137 (2011).","journal-title":"Current opinion in HIV and AIDS"},{"issue":"3","key":"48756_CR12","doi-asserted-by":"publisher","first-page":"e0150512","DOI":"10.1371\/journal.pone.0150512","volume":"11","author":"M Chen","year":"2016","unstructured":"Chen, M. et al. Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival. PloS one 11(3), e0150512 (2016).","journal-title":"PloS one"},{"issue":"9244","key":"48756_CR13","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/S0140-6736(00)03232-3","volume":"356","author":"G Greub","year":"2000","unstructured":"Greub, G. et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356(9244), 1800\u20135 (2000).","journal-title":"Lancet"},{"issue":"9397","key":"48756_CR14","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","volume":"362","author":"N Qurishi","year":"2003","unstructured":"Qurishi, N. et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362(9397), 1708\u201313 (2003).","journal-title":"Lancet"},{"key":"48756_CR15","doi-asserted-by":"crossref","unstructured":"Ding Y. et al. More Improvement than Progression of Liver Fibrosis Following Antiretroviral Therapy in A Longitudinal Cohort of HIV-infected Patients With or Without HBV and HCV Co-infections. Journal of viral hepatitis (2016).","DOI":"10.1111\/jvh.12658"},{"issue":"5","key":"48756_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/COH.0000000000000292","volume":"11","author":"MB Klein","year":"2016","unstructured":"Klein, M. B., Rockstroh, J. K. & Wittkop, L. Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Current opinion in HIV and AIDS 11(5), 521\u20136 (2016).","journal-title":"Current opinion in HIV and AIDS"},{"issue":"2","key":"48756_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/hep.23020","volume":"50","author":"J Berenguer","year":"2009","unstructured":"Berenguer, J. et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 50(2), 407\u201313 (2009).","journal-title":"Hepatology"},{"issue":"5","key":"48756_CR18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/civ396","volume":"61","author":"B Simmons","year":"2015","unstructured":"Simmons, B., Saleem, J., Heath, K., Cooke, G. S. & Hill, A. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 61(5), 730\u201340 (2015).","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"6","key":"48756_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S1665-2681(19)30977-9","volume":"13","author":"Y Maor","year":"2014","unstructured":"Maor, Y., Schapiro, J. M., Bashari, D. & Martinowitz, U. Survival of hepatitis C-infected haemophilia patients is predicted by presence of cirrhosis but not by anti-viral treatment. Annals of hepatology 13(6), 753\u201361 (2014).","journal-title":"Annals of hepatology"},{"issue":"8","key":"48756_CR20","doi-asserted-by":"publisher","first-page":"e0160460","DOI":"10.1371\/journal.pone.0160460","volume":"11","author":"A Trickey","year":"2016","unstructured":"Trickey, A. et al. Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PloS one 11(8), e0160460 (2016).","journal-title":"PloS one"},{"issue":"4","key":"48756_CR21","doi-asserted-by":"publisher","first-page":"e1001418","DOI":"10.1371\/journal.pmed.1001418","volume":"10","author":"LF Johnson","year":"2013","unstructured":"Johnson, L. F. et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS medicine 10(4), e1001418 (2013).","journal-title":"PLoS medicine"},{"issue":"1","key":"48756_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/QCO.0b013e32835ba6b1","volume":"26","author":"F Nakagawa","year":"2013","unstructured":"Nakagawa, F., May, M. & Phillips, A. Life expectancy living with HIV: recent estimates and future implications. Current opinion in infectious diseases 26(1), 17\u201325 (2013).","journal-title":"Current opinion in infectious diseases"},{"issue":"9772","key":"48756_CR23","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(10)62001-6","volume":"377","author":"D Joshi","year":"2011","unstructured":"Joshi, D., O\u2019Grady, J., Dieterich, D., Gazzard, B. & Agarwal, K. Increasing burden of liver disease in patients with HIV infection. Lancet 377(9772), 1198\u2013209 (2011).","journal-title":"Lancet"},{"issue":"3","key":"48756_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2893.2006.00791.x","volume":"14","author":"E Rosenthal","year":"2007","unstructured":"Rosenthal, E. et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). Journal of viral hepatitis 14(3), 183\u20138 (2007).","journal-title":"Journal of viral hepatitis"},{"issue":"8","key":"48756_CR25","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/QAD.0000000000000222","volume":"28","author":"P Morlat","year":"2014","unstructured":"Morlat, P. et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. Aids 28(8), 1181\u201391 (2014).","journal-title":"Aids"},{"issue":"13","key":"48756_CR26","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1097\/QAD.0000000000000377","volume":"28","author":"MB Klein","year":"2014","unstructured":"Klein, M. B. et al. Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003\u20132013). Aids 28(13), 1957\u201365 (2014).","journal-title":"Aids"},{"issue":"3","key":"48756_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/QAI.0000000000000603","volume":"69","author":"MT May","year":"2015","unstructured":"May, M. T. et al. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration. Journal of acquired immune deficiency syndromes 69(3), 348\u201354 (2015).","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"2","key":"48756_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.5812\/hepatmon.4908","volume":"12","author":"A Rezaianzadeh","year":"2012","unstructured":"Rezaianzadeh, A. et al. Impact of hepatitis C on survival of HIV-infected individuals in Shiraz; South of Iran. Hepatitis monthly 12(2), 106\u201311 (2012).","journal-title":"Hepatitis monthly"},{"issue":"18","key":"48756_CR29","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1097\/QAD.0000000000001646","volume":"31","author":"AC Thornton","year":"2017","unstructured":"Thornton, A. C. et al. Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. Aids 31(18), 2525\u201332 (2017).","journal-title":"Aids"},{"issue":"1","key":"48756_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","volume":"44","author":"N Brau","year":"2006","unstructured":"Brau, N. et al. Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. Journal of hepatology 44(1), 47\u201355 (2006).","journal-title":"Journal of hepatology"},{"issue":"1","key":"48756_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.20541","volume":"41","author":"SH Mehta","year":"2005","unstructured":"Mehta, S. H. et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 41(1), 123\u201331 (2005).","journal-title":"Hepatology"},{"issue":"3","key":"48756_CR32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jhep.2015.04.019","volume":"63","author":"H Kovari","year":"2015","unstructured":"Kovari, H. et al. High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. Journal of hepatology 63(3), 573\u201380 (2015).","journal-title":"Journal of hepatology"},{"issue":"2","key":"48756_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jhep.2013.04.005","volume":"59","author":"JK Rockstroh","year":"2013","unstructured":"Rockstroh, J. K. et al. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? Journal of hepatology 59(2), 213\u201320 (2013).","journal-title":"Journal of hepatology"},{"issue":"6","key":"48756_CR34","first-page":"369","volume":"160","author":"RV Lo 3rd","year":"2014","unstructured":"Lo, R. V. 3rd et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals of internal medicine 160(6), 369\u201379 (2014).","journal-title":"Annals of internal medicine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48756-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48756-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48756-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:59:32Z","timestamp":1671281972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48756-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48756"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48756-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,29]]},"assertion":[{"value":"23 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12502"}}